Reusable Bioreactors Market (2026 - 2033)

Reusable Bioreactors Market Summary

The global reusable bioreactors market size was valued at USD 8.2 billion in 2025 and is projected to grow from USD 9.3 billion in 2026 to USD 30.9 billion by 2033, at a CAGR of 18.7% from 2026 to 2033. North America dominated the market, accounting for the largest revenue share of 34.6% in 2025. The growth is driven by the rising adoption of reusable bioreactors for cost-effective, scalable, and sustainable biopharmaceutical manufacturing processes globally.

The industry is witnessing significant growth, driven by increasing demand for scalable and cost-efficient bioprocessing across pharmaceutical, biotechnology, food, and industrial applications. The ability of reusable bioreactors to support repeated production cycles and large-scale operations is encouraging manufacturers to adopt these systems for greater equipment utilization and lower long-term operating costs.

Market Dynamics

The growing focus on sustainable bioprocessing and reducing waste from disposable systems is supporting market expansion. Moreover, advances in bioreactor design, automation, process monitoring, and reusable materials are improving operational flexibility and process efficiency, further supporting market growth over the forecast period.

Market Concentration & Characteristics

The industry is witnessing ongoing innovation, with manufacturers focusing on improvements in reactor design, process control, automation, mixing, aeration, and monitoring. Stainless-steel and glass bioreactor systems are being enhanced to improve scalability, reproducibility, and operational efficiency, while sensor integration and automated controls enable more precise monitoring of cultivation conditions. These developments are focused on enhancing the performance, reliability, flexibility, and consistency of reusable bioreactor systems across research, process development, and commercial bioprocessing applications.

The industry is seeing M&A activity as companies strengthen their bioreactor design, fermentation, and bioprocessing capabilities. For instance, in December 2025, Tetra Pak acquired Bioreactors.net, a company specializing in the design and manufacture of bioreactor systems for biomass and precision fermentation. The acquisition added bioreactor design and upstream fermentation expertise to Tetra Pak’s portfolio, strengthening its ability to provide integrated bioreactor and fermentation solutions across different production scales.

“The addition of Bioreactors.net complements our existing upstream and downstream processing portfolio with fermentation capabilities. Together, we will deploy their full portfolio of bioreactor solutions under the Tetra Pak brand, offering advanced food production systems. This acquisition will enable us to accelerate the development of next-generation bioreactors, empowering both emerging innovators and established producers to scale sustainably.”

- Rafael Barros, Director of the New Food Business Stream at Tetra Pak.

Regulations affect the industry through GMP requirements for equipment qualification, cleaning, sterilization, contamination control, and process validation. These requirements are important for stainless steel and glass bioreactors, which are cleaned and sterilized between production batches. Manufacturers, therefore, need effective CIP/SIP procedures, process monitoring, automation, and proper documentation to maintain consistent operating conditions and meet quality standards in biopharmaceutical manufacturing.

The industry is witnessing developments in large-scale stainless-steel systems to support higher-volume biopharmaceutical production. For instance, in December 2024, Boston Institute of Biotechnology and BiBo Pharma announced an expansion including 30,000-L, 15,000-L, and 5,000-L stainless-steel bioreactors, adding more than 150,000 L of mammalian cell-culture working volume. The expansion increases large-scale manufacturing capacity and supports the growing need for high-capacity reusable bioreactor systems in biologics production.

The industry is witnessing regional development as biopharmaceutical manufacturing capacity grows across different markets. Stainless-steel bioreactors continue to support large-scale production due to their durability and suitability for repeated use. Moreover, companies are strengthening manufacturing, engineering, and service capabilities, supporting wider adoption of reusable bioreactor systems in commercial bioprocessing.

Analyst Perspective

The industry is driven by increasing demand for scalable, cost-effective, and sustainable bioprocessing solutions across biopharmaceutical manufacturing. Rising adoption of reusable systems for repeated production cycles, particularly in large-scale biologics manufacturing, is supporting market expansion. Advancements in bioreactor design, automation, process monitoring, and reusable materials are further improving operational efficiency, flexibility, and process consistency. Market participants are focusing on large-scale stainless-steel systems, advanced process-control technologies, sustainable materials, and customized bioreactor solutions to address the growing requirements of pharmaceutical and biopharmaceutical manufacturers, CROs, and CDMOs.

Product Insights

The reusable bioreactor systems segment accounted for the largest revenue share of 42.4% in 2025. The growth is supported by the established use of stainless-steel systems in large-scale biopharmaceutical manufacturing. These systems offer durability, scalability, and repeated use, making them suitable for commercial cell culture and production. For instance, in December 2025, HOLVES launched the Omini Cell510 stainless-steel bioreactor for process development, scale-up, and GMP clinical sample production. The use of reusable systems in large-scale biopharmaceutical manufacturing is helping to maintain the segment’s leading position.

The reusable bioreactor accessories & components segment is expected to grow at a significant CAGR during 2026-2033, supported by the continued use of reusable systems in biopharmaceutical manufacturing and research. Demand for sensors, probes, impellers, valves, fittings, headplates, and other components is increasing with system installation, maintenance, and replacement requirements. The need for reliable process monitoring and regular replacement of components used in reusable systems is expected to support segment growth over the forecast period.

Bioreactor Type Insights

The stirred-tank bioreactors segment dominated the market with a share of 24.7% in 2025, supported by its established use in reusable systems for cell culture and biopharmaceutical manufacturing. These systems provide controlled agitation, oxygen transfer, pH, and temperature, making them suitable for process development and large-scale production. Moreover, their scalability and established use across biopharmaceutical manufacturing processes are expected to drive segment growth during the forecast period.

The packed-bed bioreactors segment is expected to register a significant CAGR during 2026-2033, driven by its use in high-density adherent-cell culture for biopharmaceutical and cell therapy applications. These systems provide a large surface area for cell attachment and facilitate nutrient and oxygen transfer, enabling efficient cell expansion. Growing demand for adherent-cell manufacturing is likely to strengthen the adoption of packed-bed systems.

Application Insights

The monoclonal antibodies segment accounted for 19.5% of the total revenue in 2025, making it the leading segment, mainly due to rising demand for antibody-based therapies across oncology, immunology, and other therapeutic areas. The increasing use of monoclonal antibodies is creating demand for additional manufacturing capacity, including reusable bioreactor systems used for large-scale production. According to an article published in mAbs in February 2025, rising demand for antibody therapeutics was reported to increase the need for additional biomanufacturing capacity, particularly for large-scale mAb production. This increase in mAb manufacturing demand supports the segment growth during the forecast period.

The microbial products segment is projected to grow with a significant CAGR during 2026-2033, driven by increasing production of vaccines, enzymes, antibiotics, recombinant proteins, and other microbial-derived products. Reusable bioreactors provide controlled fermentation conditions and support repeated production runs across different scales. Growing demand for microbial-based products and expansion of biopharmaceutical manufacturing are supporting the use of reusable bioreactors in this application.

End Use Insights

The pharmaceutical & biopharmaceutical companies segment accounted for 31.8% of the global revenue in 2025, driven by the expansion of biopharmaceutical manufacturing and increasing demand for scalable production capacity. Reusable bioreactors are used in large-scale cell culture and microbial processes, particularly where repeated production, established cleaning procedures, and long-term equipment use are required. Growing biopharmaceutical manufacturing capacity is anticipated to drive the use of reusable bioreactor systems across pharmaceutical companies.

The CROs & CDMOs segment is projected to witness significant growth during 2026-2033, driven by increasing outsourcing of biopharmaceutical development and manufacturing. Growing demand for process development, scale-up, and commercial production services is expanding the role of CROs and CDMOs in biopharmaceutical manufacturing. Rising outsourcing by pharmaceutical companies is expected to increase demand for reusable bioreactor systems.

Regional Insights

The North America reusable bioreactors market accounted for the largest revenue share of 34.6% in 2025, driven by the region’s well-established biopharmaceutical manufacturing infrastructure, widespread adoption of large-scale stainless-steel bioreactor systems, and the presence of major biologics manufacturers with established production facilities. Reusable bioreactors remain particularly relevant for high-volume and repeated manufacturing campaigns because of their durability, established scale-up processes, cleanability, and compatibility with CIP/SIP operations.

U.S. Reusable Bioreactors Market Trends

The reusable bioreactors market in the U.S. is expected to grow significantly over the forecast period, supported by a large-scale biopharmaceutical manufacturing base and continued use of stainless-steel systems for commercial production. In addition, the expansion of cell-culture manufacturing capacity is creating demand for high-capacity reusable bioreactors, particularly for processes requiring established cleaning and sterilization infrastructure. The availability of large-scale stainless-steel systems is further supporting their use in commercial biologics manufacturing.

Europe Reusable Bioreactors Market Trends

The reusable bioreactors market in Europe is supported by an established biopharmaceutical manufacturing base and continued use of stainless-steel systems for large-scale production. In addition, well-developed GMP infrastructure and established bioprocessing facilities support the demand for durable and repeatedly sterilizable bioreactors, particularly for high-volume manufacturing processes.

The UK reusable bioreactors market is supported by the availability of multi-use systems across laboratories, scale-up, and production applications. For instance, in May 2024, TECNIC appointed Biopharma Group as its exclusive distributor for the UK and Ireland, making its bioreactor systems available in stainless-steel multi-use and single-use formats from benchtop to production scale. The partnership expands access to stainless-steel multi-use bioreactors across different bioprocessing requirements, supporting market development in the UK.

The reusable bioreactors market in Germany is anticipated to grow significantly over the forecast period, supported by its established biopharmaceutical manufacturing base and expertise in bioprocess engineering. In addition, the continued use of stainless-steel systems for large-scale cell and microbial cultivation is supporting demand for reusable equipment, while established bioprocessing facilities are strengthening their use across development and production applications.

Asia Pacific Reusable Bioreactors Market Trends

The reusable bioreactors market in Asia Pacific is expected to grow at the fastest CAGR of 20.2% during the forecast period, by expanding biopharmaceutical manufacturing capacity, increasing investments in biologics production facilities, and rising demand for large-scale bioprocessing equipment. Moreover, the expansion of domestic pharmaceutical manufacturing and production capacity is increasing the need for scalable production systems, supporting the use of reusable bioreactors for commercial-scale and repeated biopharmaceutical manufacturing.

The China reusable bioreactors industry is witnessing strong growth, supported by the expansion of large-scale biologics manufacturing and increasing adoption of stainless-steel production systems. For instance, in June 2025, two 10,000-L stainless-steel bioreactor production lines for trastuzumab and bevacizumab biosimilars were approved for use in China. The production lines had completed more than 50 drug-substance batches and over 120 drug-product batches, supporting the use of large-scale reusable bioreactors in commercial biologics manufacturing.

The reusable bioreactors market in Japan is witnessing rapid growth driven by the country’s established pharmaceutical manufacturing base and focus on process development. Moreover, demand for controlled and reproducible cultivation systems is supporting the use of multi-use bioreactors across research and production. Established bioprocessing capabilities are further supporting demand for reusable systems in scale-up and commercial manufacturing.

Latin America Reusable Bioreactors Market Trends

The reusable bioreactors industry in Latin America is growing steadily, supported by the expansion of biopharmaceutical manufacturing and increasing local production of biological medicines. In addition, investments in manufacturing facilities are creating demand for bioprocessing equipment, including reusable systems used for repeated production and established GMP processes. The expansion of biological manufacturing capacity is expected to support the adoption of reusable bioreactors for commercial-scale production.

MEA Reusable Bioreactors Market Trends

The reusable bioreactors industry in the Middle East & Africa is expected to grow gradually, driven by the expansion of local biopharmaceutical manufacturing, increasing investments in biologics production infrastructure, and efforts to strengthen regional pharmaceutical self-sufficiency. For instance, in May 2025, Saudi Arabia inaugurated MS Pharma’s biologics manufacturing plant in Riyadh, the country’s first facility for producing fully formulated biologic drugs, supporting the localization of pharmaceutical manufacturing. The expansion of regional biologics manufacturing capacity is helping to create opportunities for bioprocessing equipment suppliers.

Key Reusable Bioreactors Companies Insights

The reusable bioreactors market includes established companies offering bioreactor systems, stainless-steel vessels, and specialized equipment for cell culture, microbial fermentation, and large-scale bioprocessing. Key players, including Eppendorf SE, Pierre Guérin (a subsidiary of Equans), GEA Group, ZETA, ABEC, Inc., Infors AG, Solaris Biotech, bbi-biotech, Getinge AB, and Actini Group strengthen their market positions through product development, customized bioreactor solutions, expanded production capabilities, advanced process control, and continued investment in bioprocessing technologies.

Key Reusable Bioreactors Companies

The following key companies have been profiled for this study on the reusable bioreactors market.

• Eppendorf SE

• Pierre Guérin (a subsidiary of Equans)

• GEA Group

• ZETA

• ABEC, Inc.

• Infors AG

• Solaris Biotech

• bbi-biotech

• Getinge AB

• Actini Group

Competitive Benchmarking

Recent Developments

• In March 2024, ZETA Group acquired SIGMA Process & Automation GmbH to strengthen its pharmaceutical process automation and digitalization capabilities, supporting advanced automation and control of biopharmaceutical manufacturing processes, including applications relevant to bioreactor operations.

"The joining of our resources ensures that our customers benefit from the highest possible value of expertise and experience from our two companies. Together, we offer a perfect network and comprehensive services that are close to our customers"

- Andreas Marchler, CEO of ZETA Group

Reusable Bioreactors Market Report Scope

Global Reusable Bioreactors Market Report Segmentation

This report forecasts revenue growth at the global, regional, and country levels and provides an analysis of the latest trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global reusable bioreactors market report on the basis of product, bioreactor type, application, end use, and region:

• Product Outlook (Revenue, USD Billion, 2021 - 2033)

  • Reusable Bioreactor Systems

    • Up to 10 L

    • 11-100 L

    • 101-500 L

    • 501-1,500 L

    • Above 1,500 L

  • Reusable Bioreactor Accessories & Components

  • Others

• Bioreactor Type Outlook (Revenue, USD Billion, 2021 - 2033)

  • Stirred-tank Bioreactors

  • Air-lift Bioreactors

  • Bubble-column Bioreactors

  • Packed-bed Bioreactors

  • Other Bioreactors

• Application Outlook (Revenue, USD Billion, 2021 - 2033)

  • Monoclonal Antibodies

  • Vaccines

  • Recombinant Proteins

  • Cell & Gene Therapies

  • Microbial Products

  • Other Applications

• End Use Outlook (Revenue, USD Billion, 2021 - 2033)

  • Pharmaceutical & Biopharmaceutical Companies

  • CROs & CDMOs

  • Academic & Research Institutes

  • Other End Users

• Regional Outlook (Revenue, USD Billion, 2021 - 2033)

  • North America

    • U.S.

    • Canada

    • Mexico

  • Europe

    • UK

    • Germany

    • France

    • Italy

    • Spain

    • Denmark

    • Sweden

    • Norway

  • Asia Pacific

    • Japan

    • China

    • India

    • Australia

    • Thailand

    • South Korea

  • Latin America

    • Brazil

    • Argentina

  • Middle East and Africa (MEA)

    • South Africa

    • Saudi Arabia

    • UAE

    • Kuwait

Research Methodology

The reusable bioreactors market figures in this report are based on a proven research process that combines executive interviews with secondary research from proprietary databases, company filings, and recognized regulatory and institutional sources. Market size is built through value-chain sizing-reconciling supply-side and demand-side estimates-and triangulated with bottom-up and top-down approaches. Every estimate passes multiple levels of expert validation before publication, with each reusable bioreactors segment quantified using the revenue-capture definitions in the table below.

Segment Definition

Delivered Customizations

This report has been delivered with the following In-depth customizations